MedTrace Logo

Safety and Tolerability of IRX-101 in Patients Receiving Intravitreal Injections

NCT05750589 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 240

Last updated 2026-04-03

No results posted yet for this study

Summary

This is a randomized, double-masked study to evaluate the tolerability and safety of IRX-101 versus 5% povidone-iodine (PI) in subjects receiving intravitreal anti-VEGF injections.

Conditions

  • Retinal Disease

Interventions

DRUG

IRX-101

IRX-101 is a novel ocular anti-septic

DRUG

Providone-Iodine

5% Providone-Iodine

Sponsors & Collaborators

  • iRenix Medical, Inc.

    lead INDUSTRY

Principal Investigators

  • Stephen Smith, MD · Founder

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-09-01
Primary Completion
2027-01-31
Completion
2027-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05750589 on ClinicalTrials.gov